Table 1 Clinicopathologic and molecular characteristics of patients with DLBCL with a low or high degree of SHM in immunoglobulin variable region genes
| Â | IGHV SHMlow | IGHV SHMhigh | P | IGK/LV SHMlow | IGK/LV SHMhigh | P |
|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | |||
Age | ||||||
  < 60 years | 32 (44%) | 25 (36%) | .31 | 66 (40%) | 14 (37%) | .72 |
  ≥ 60 years | 40 (56%) | 45 (64%) |  | 97 (60%) | 24 (63%) |  |
Sex | ||||||
 Male | 35 (49%) | 41 (59%) | .24 | 94 (58%) | 26 (68%) | .27 |
 Female | 37 (51%) | 29 (41%) |  | 69 (42%) | 12 (32%) |  |
Stage | ||||||
 I - II | 29 (43%) | 34 (52%) | .39 | 72 (46%) | 14 (39%) | .58 |
 III - IV | 39 (57%) | 32 (48%) |  | 86 (54%) | 22 (61%) |  |
B symptoms | ||||||
 No | 38 (56%) | 43 (63%) | .48 | 103 (66%) | 28 (78%) | .23 |
 Yes | 30 (44%) | 25 (37%) |  | 53 (34%) | 8 (22%) |  |
Serum LDH level | ||||||
 Normal | 21 (33%) | 29 (45%) | .20 | 67 (46%) | 18 (55%) | .44 |
 Elevated | 43 (67%) | 35 (55%) |  | 78 (54%) | 15 (45%) |  |
No. of extranodal sites | ||||||
 0 or 1 | 51 (76%) | 53 (82%) | .53 | 126 (81%) | 26 (70%) | .18 |
  ≥ 2 | 16 (24%) | 12 (18%) |  | 30 (19%) | 11 (30%) |  |
ECOG performance status | ||||||
 0 or 1 | 47 (80%) | 44 (76%) | .66 | 113 (79%) | 26 (81%) | 1.0 |
  ≥ 2 | 12 (20%) | 14 (24%) |  | 30 (21%) | 6 (19%) |  |
Largest tumor size | ||||||
  < 5 cm | 37 (66%) | 27 (53%) | .17 | 73 (57%) | 13 (43%) | .22 |
  ≥ 5 cm | 19 (34%) | 24 (47%) |  | 55 (43%) | 17 (57%) |  |
IPI score | ||||||
 0–2 | 40 (60%) | 42 (64%) | .72 | 97 (62%) | 21 (57%) | .58 |
 3–5 | 27 (40%) | 24 (36%) |  | 60 (38%) | 16 (43%) |  |
Therapy response | ||||||
 CR | 51 (71%) | 54 (77%) | .45* | 126 (77%) | 27 (73%) | .67* |
 PR | 10 | 8 |  | 21 | 3 |  |
 SD | 2 | 3 |  | 4 | 1 |  |
 PD | 9 | 5 |  | 12 | 6 |  |
ABC subtype/ABC subtype | ||||||
 GCB | 27 (39%) | 39 (53%) | .094 | 78 (47%) | 21 (57%) | .36 |
 ABC | 43 (61%) | 34 (47%) |  | 88 (53%) | 16 (43%) |  |
BAGS classification | ||||||
 CC/CB | 24 (52%) | 40 (75%) | .02 | 77 (64%) | 21 (81%) | .11 |
 Others | 22 (48%) | 13 (25%) |  | 43 (36%) | 5 (19%) |  |
BCL2 translocation | ||||||
 No | 55 (87%) | 46 (72%) | .047 | 125 (81%) | 22 (65%) | .042 |
 Yes | 8 (13%) | 18 (28%) |  | 29 (19%) | 12 (35%) |  |
MYC expression | ||||||
 < 70% | 39 (57%) | 50 (72%) | .047 | 117 (72%) | 26 (68%) | .69 |
 ≥ 70% | 29 (43%) | 19 (28%) |  | 46 (28%) | 12 (32%) |  |
PI3K expression | ||||||
 < 70% | 43 (67%) | 50 (75%) | .44 | 112 (72%) | 14 (42%) | .0018 |
 ≥ 70% | 21 (33%) | 17 (25%) |  | 43 (28%) | 19 (58%) |  |
p63 expression | ||||||
 < 10% | 47 (68%) | 38 (54%) | .086 | 93 (59%) | 14 (39%) | .04 |
 ≥ 10% | 22 (32%) | 33 (46%) |  | 65 (41%) | 22 (61%) |  |
CD30 expression | ||||||
  < 20% | 58 (83%) | 60 (83%) | 1.0 | 135 (82%) | 37 (97%) | .012 |
  ≥ 20% | 12 (17%) | 12 (17%) |  | 30 (18%) | 1 (3%) |  |
p65 expression | ||||||
  < 10% | 22 (35%) | 29 (43%) | .47 | 61 (41%) | 7 (21%) | .031 |
  ≥ 10% | 40 (65%) | 39 (57%) |  | 89 (59%) | 27 (79%) |  |
CXCR4 expression | ||||||
  < 20% | 43 (73%) | 47 (70%) | .84 | 109 (72%) | 19 (53%) | .029 |
  ≥ 20% | 16 (27%) | 20 (30%) |  | 42 (28%) | 17 (47%) |  |